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Exploring Data Quality Management within Clinical Trials
Abstract
Background Clinical trials are an important research method for improving medical knowledge and
patient care. Multiple international and national guidelines stipulate the need for data quality and
assurance. Many strategies and interventions are developed to reduce error in trials, including standard
operating procedures, personnel training, data monitoring, and design of case report forms. However,
guidelines are nonspecific in the nature and extent of necessary methods.
Objective This article gathers information about current data quality tools and procedures used within
Australian clinical trial sites, with the aim to develop standard data quality monitoring procedures to
ensure data integrity.
Methods Relevant information about data quality management methods and procedures, error levels,
data monitoring, staff training, and development were collected. Staff members from 142 clinical trials
listed on the National Health and Medical Research Council (NHMRC) clinical trials Web site were invited
to complete a short self-reported semiquantitative anonymous online survey.
Results Twenty (14%) clinical trials completed the survey. Results from the survey indicate that
procedures to ensure data quality varies among clinical trial sites. Centralized monitoring (65%) was the
most common procedure to ensure high-quality data. Ten (50%) trials reported having a data
management plan in place and two sites utilized an error acceptance level to minimize discrepancy, set at
<5% and 5 to 10%, respectively. The quantity of data variables checked (10–100%), the frequency of visits
(once-a-month to annually), and types of variables (100%, critical data or critical and noncritical data
audits) for data monitoring varied among respondents. The average time spent on staff training per
person was 11.58 hours over a 12-month period and the type of training was diverse.
Conclusion Clinical trial sites are implementing ad hoc methods pragmatically to ensure data quality.
Findings highlight the necessity for further research into “standard practice” focusing on developing and
implementing publicly available data quality monitoring procedures.
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Abstract
Background: Clinical trials are an important research method for improving medical
knowledge and patient care. Multiple international and national guidelines stipulate the
need for data quality and assurance. Many strategies and interventions are developed to
reduce error in trials, including standard operating procedures, personnel training, data
monitoring and design of case report forms. However, guidelines are non-specific in the
nature and extent of necessary methods. Objective: To gather information about current
data quality tools and procedures used within Australian clinical trial sites, with the aim
to develop standard data quality monitoring procedures to ensure data integrity.
Methods: Relevant information about data quality management methods and procedures,
error levels, data monitoring, staff training, and development were collected. Staff
members from 142 clinical trials listed on the National Health and Medical Research
Council (NHMRC) clinical trials website were invited to complete a short self-reported
semi-quantitative anonymous online survey. Results: Twenty (14%) clinical trials
completed the survey. Results from the survey indicate that procedures to ensure data
quality varies among clinical trial sites. Centralized monitoring (65%) was the most
common procedure to ensure high-quality data. Ten (50%) trials reported having a data
management plan in place and two sites utilized an error acceptance level to minimize
discrepancy, set at <5% and 5-10%, respectively. The quantity of data variables checked
(10-100%), the frequency of visits (once-a-month to annually), and types of variables
(100%, critical data or critical and non-critical data audits) for data monitoring varied
among respondents. The average time spent on staff training per person was 11.58 hours
over a 12-month period and the type of training was diverse. Conclusion: Clinical trial
sites are implementing ad-hoc methods pragmatically to ensure data quality. Findings
highlight the necessity for further research into “standard practice” focusing on
developing and implementing publically available data quality monitoring procedures.
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1. Background and Significance
Clinical trials are an important research method for improving medical knowledge
and patient care. Evidence has linked poor data quality to incorrect conclusions and
recommendations [1-4]; therefore, data quality is of paramount importance for acquiring
reliable research findings from clinical trials [5, 6]. As poor data quality may stem from
error; therefore, preventing data error is just as important as the development, design, and
collection of clinical trial data [7]. Assessment of all possible sources of error, including
data recording, abstraction, transcription, entry, coding and/or cleaning processes,
contributes to improving data quality for clinical trials [8].
Many strategies and interventions have been developed aiming at reducing error in
clinical trials, including standard operating procedures (SOPs), personnel training, data
monitoring and design of case report forms (CRF). Additionally, multiple international
and national guidelines stipulate the need for data quality and assurance, however, they
are non-specific in the nature and extent of the necessary methods. These guidelines
include the International Conference on Harmonisation Good Clinical Practice
(ICHGCP) guideline E6 (1996)[9] updated in 2015, guideline E6(R2)[10]; the
International Standards Organisation (ISO) Clinical Investigation of Medical Devices for
Human Subjects – GCP (2011) (ISO 14155:2011)[11]; the Food and Drug Administration
(FDA) Guidelines for Monitoring of Clinical Investigations (1998) updated in 2013[12];
the European Union’s Clinical Trial Directive 2001/20/EC (2001)[13], updated in 2009
and the Australian Government’s National Statement on Ethical Conduct in Human
Research, (1999), updated, in 2007[14].

According to ICHGCP, clinical trials must protect the rights and safety of all patients
and ensure trial results are legible and valid. On-site monitoring is important to achieve
high data quality and to ensure the method of source data verification1 (SDV) fulfils the
original objectives [15].To optimize the efficacy of monitoring there has been an
emphasis on data audits and reducing on-site monitoring [10, 11]. However, the ICHGCP
guidelines are flexible in interpretation and do not provide specific details on how and
when to conduct audits, or how much or how little monitoring is required to maintain
data integrity [16, 17]. There is a lack of evidence to support intensive monitoring for
data quality, in fact, updated guidelines promote alternative monitoring methods, such as
risk-based approaches2, centralized3 and remote monitoring4, that complement trial
procedures by improving the use of resources available [12, 18-20]. Although a reduction
in on-site monitoring is suggested (updated ICHGCP guidelines re [21, 22]), the majority
of clinical trials continue to conduct traditional 100% SDV[23]. Lack of clear guidance
on which monitoring method is valid and cost-effective to ensure data integrity creates
confusion within the clinical research community. A reduction in on-site SDV and the
risk of missing critical issues are tradeoffs that more efficient, modern monitoring
approaches need to consider.

1

Source data verification (SDV) defines the process of comparing data collected on original source
documents to data recorded on a case report form (CRF) either on paper or electronic records
2
Risk-based approach includes a mixed method approach focused on the critical data points an
processes that are identified to have the most risk via a targeted or triggered assessment.
3
Centralized monitoring is a remote evaluation carried out by the sponsor personnel or representatives
at a location other than the sites at which the clinical investigation is being carried out on a real time basis.
4
Remote monitoring is off-site monitoring of activities previously conducted on-site. Documents are
delivered via email, fax or snail mail to a clinical research associate (CRA) to conduct SDV and satisfy
queries.

Due to a growing concern about the effectiveness and efficiency of monitoring
procedures, Brosteanu et al. (2017) conducted a clustered randomised study comparing
intensive on-site monitoring and risk-adapted monitoring. Results found the benefit of
intensive on-site SDV to be small (8.2%) when compared to risk-based monitoring,
which utilized less than 50% of resources whilst ensuring the same level of GCP
compliance [18]. It is evident that standardized approach needs to be adopted for
monitoring of data quality in clinical research. In support of this notion, a survey
conducted by the Clinical Trials Transformation Initiative (CTTI) investigated the
intensity, focus, and methodology of monitoring practices by clinical research sponsors
over a range of trial settings [24]. It was found that there is heterogeneity within and
between organizational types including academic/government, clinical research
organizations, and industry.
Evidence of the effect of non-standardized data quality checks within clinical
trials is the online blog of publication retractions due to fraudulent data [25]. This website
lists 484 publications in 2017 alone that had to be withdrawn due to incorrect
data/analysis. There appears to be a lack of knowledge about systematic methods and
procedures for data quality assessment in clinical trials [1].To ensure data integrity in
clinical research it is imperative to introduce a ‘gold standard methodology’ so that
manuscripts can be published referencing their methods employed and the broader
research community can be reassured the data was valid.

2. Objectives
The objective of this feasibility study was to gather information about current data
quality tools and procedures used within Australian clinical trial sites, with the aim to
develop a standard data quality monitoring procedures to ensure data integrity.

3. Methods
3.1. Setting
Clinical trial sites listed on the Australian Government National Health and
Medical Research Council (NHMRC) Australian Clinical Trial site list were invited to
participate in this survey (n=148) [5, 26]. Employees targeted to complete the survey
included the manager/employee in charge of trial-related data quality assurance
processes. The NHMRC clinical trial list was determined as a representative sample of
Australian clinical trials including all phases (I-IV) and types (treatment,
diagnostic/screening, and prevention) of clinical trials.
Clinical trial sites that were identified to have an affiliation with the University of
Wollongong (UoW), the organization that the researchers were employed, were excluded
from the study to avoid the potential risk of bias. Any overlapped sites which, may cause
duplication, were also excluded. Several clinical trial networks on the list responded that
they did not run clinical trials independently. In this case, permission was given for these
networks to forward the survey to their collaborating organizations that run clinical trials.
Informed tacit consent was obtained by completion and return of the online questionnaire
survey form.

3.2. Development of the online questionnaire survey form
Eleven survey questions were adapted in short form from the published and
validated survey questions [24, 27]. Information gathered from the survey included data
quality management methods and procedures, error levels, data monitoring, staff training,
and development (see Appendix A).
Construct validation was completed by a convenience sample of ten UoW
researchers who reviewed survey questions to ensure that the intended concept was
assessed. Participants were also asked to comment on any procedural, usability and
transparency issues faced in completing the survey. Expert advice from a data
management manager was sought to ensure content validity, question clarity and answers
fully address the research questions. The online questionnaire survey was designed using
the Research Electronic Data Capture (REDCap) tool hosted at the University of
Wollongong [28].

3.3. Survey administration
A cross-sectional study design was applied to get an overview of the current
quality tools and practices implemented in Australian clinical trials. Invitations for
participation were sent to the identified contact person for each clinical trial site via
email. The email contained a brief introduction and a direct link to the survey. Each
clinical trial site was provided with an individual identification code and three email
reminders were sent over a four-month period to non-respondents. Clinical trial sites were
asked to forward the survey to their collaborating sites using the same individual
identification code if they were identified to be clinical institute network.

3.4. Data analysis
Questionnaire responses were standardized into categorical options and
numerically coded for analysis. Statistical analyses were conducted using IMB SPSS
software (Version 22, IMB Australia, Lane Cove, NSW, Australia). Data was explored
via descriptive statistical analyses. Free text responses were analyzed using the six phases
of thematic analysis [29] and conducted using NVivo qualitative data analysis Software
(QRS International Pty Ltd. Version 10, 2012). Ethics approval was obtained from the
University of Wollongong Human Research Ethics Committee (HE16/131).

4. Results
Of the 148 clinical trial sites identified, 142 initial invitations were sent out, see
Figure 1. A total of 34 clinical trial sites consented to participate in the online survey,
yielding a response rate of 24%. Of the 34 responses, 14 were excluded from the analyses
due to missing data for >25% of survey questions. Three clinical networks asked to
forward the survey invitation email to respondents that were more appropriate as well as
to their collaborating sites. Finally, 20 clinical trial sites completed the survey in full and
were included in data analysis. Table 1 listed the number and types of clinical trial sites.
At each site, more than one type of clinical trial was conducted at any point in time.

4.1. Data management and monitoring
At the time of the survey, ten sites (50%) reported having a clinical data
management plan in place and the majority (n=19) had implemented at least one or more
procedures to ensure data quality (see Table 2). Only two sites set an error acceptance

level, <5% and 5-10%, respectively, both responding that no follow-up or further
monitoring was conducted if the error rate was found to be higher than the error
acceptance level.
The structure of data monitoring was reported in terms of variables to be selected,
its coverage and amount, and time of execution. Monitoring 100% of the data points was
the most common (n=7) response, although the procedures implemented varied greatly,
and the amount of data included in monitoring ranging from 10-100%. The timing of data
monitoring varied and was specific to the clinical trial and study design. The frequency of
data monitoring varied among the six sites (30%) from monthly to annually. The
variables included in data monitoring were completed on all (100%) data points (n=5),
only critical data points (n=1), critical and non-critical data points defined by each study
(n=3) or were dependent on the clinical trial (n=3). When asked about how their data was
monitored, seven sites (35%) reported that they implemented at least one or more
sampling techniques to extract data points, seven sites (35%) did not know and one site
(5%) did not implement sampling techniques at all, see table 2 for further details.

4.2. Training and development
A certain type of staff training and development devoted to data quality were
conducted at all clinical trial sites (100%, see Table 3). The average amount of time spent
on staff training and development per person, per clinical trial was 11.58 ± 9.01 hours,
(range 2 to 30) over a 12-month period.
The personnel responsible for reviewing the reports of data quality and
consistency varied from chief investigators (65%), auditor/monitor (60%), the data

manager (55%) and sponsor (50%). In total, 75% of respondents answered that more than
one person reviewed the reports.

5. Discussion
This feasibility study highlights the heterogeneity of data quality management
practices within Australian clinical trials. Only 50% of the respondent clinical trial sites
currently had a clinical data management plan in place, confirming our proposition that
developing and maintaining a data management system is a challenge for clinical trials
[30]. This is also in accordance with a recently published survey (26). This survey
reported considerable variation in data management, with over 50% of clinical research
centres having a data management system but many did not comply with guidelines and
legal requirements (GCP and FDA)[27]. There are many reasons for this, such as
individual clinical trials implementing different procedures dictated by the sponsor, or
monetary constraints in academic versus pharmaceutical clinical trials [31].
Centralised and remote monitoring were found to be the most common data
monitoring methods utilized although there appeared to be a lack of credible literature to
suggest the advantage of these ‘newer’ methods over the more traditional approaches
[20]. This study identified that 50% of sites still use traditional data monitoring methods
such as 100% on-site SDV, which is an expensive, labor-intensive activity [32] and does
not guarantee error-free results [33]. Andersen et al. [34] compared the effect of partial
SDV and traditional 100% SDV using post hoc analyses of three-phase III randomised
control trials. Because completing traditional 100% SDV monitoring only reduced error

marginally (0.26%) compared to partial SDV, the authors challenged the belief that a 0%
error rate is not an achievable goal. Only 2 out of 20 trial sites in our survey reported
having a set error acceptance level, being ≤10%, which is in line with published literature
[8, 35, 36]. One of the two clinical trial sites stated that they implemented a 5-10%
threshold range, however, no further comment on why or when a different threshold for
data validation was adhered to. As the survey was administered to clinical trial sites, the
researchers have assumed that it might be possible that different clinical trial types have a
tighter threshold than others; for example, a 5% threshold for a phase IV trials compared
to 10% for epidemiological trials. Future research is required to explore the rationale for
different levels of error acceptance within clinical trials.
The major quality assurance activity reported to ‘prevent’ data errors was regular
education and training of data collectors throughout the clinical trial. Although the
majority of survey respondents reported that staff training and development was
undertaken, the amount of training time varied greatly. Many researchers receive little to
no training in regards to best practice for attaining, evaluating and controlling the quality
of data collected. This is in line with the literature that reported due to the limitation of
time and resources, not all research trials implement all the necessary data quality
management tools and procedures [37].
Within the pharmaceutical/private industries [38] and information sciences
literature, data quality tools and procedures are well developed in which many
frameworks acknowledge the multiple dimensions of data quality [39-44]. However, only
a small body of clinical and health researchers have described the use of data quality
frameworks [38, 45-48], and fewer have identified appropriate methods to quantify the

quality of data [8]. Although many data quality dimensions and attributes have been
determined within the clinical and health literature, the majority provides no usable
definitions. Public sharing of this knowledge is crucial in developing a standardized
approach that can be implemented across the clinical and broader research community to
improve the rigor of clinical trials.

5.1 Study limitations
The results of this feasibility study are limited to clinical trials listed on the
Australian NHMRC clinical trial site list. The survey results are subject to potential bias
in a positive direction as the employee who completed the survey may be more
knowledgeable about their organization’s data quality management procedures than those
who chose to not participate. As clinical trial sites were recruited as an organization it is
impossible for us to track if the person who completed the survey was best positioned to
do so in the organization. In addition, the tools and procedures differed among clinical
trials, which were influenced by overarching site policies. All these cause difficulty in
interpreting results. The reason for low response rate might be clinical data audits and
data management procedures are usually considered highly confidential by many research
organizations and kept in-house [49]. As it is impossible to collect data about how many
forwarding e-mails were sent by the clinical trial sites listed on the NHMRC website, this
data was not accounted for in calculating a response rate. The low response rate means
that the results of this survey should be used with caution. They may not be generalizable
as a representative sample of clinical trial sites. Future research should include qualitative
analysis through key-informant interviews with the provision of SOPs. This feasibility
study was not designed to assess which data management tool is more effective, but

rather to gather information about current data quality tools and procedures used within
Australian clinical trials. Further research is required to fully examine the best method of
monitoring data quality to assure and control data integrity in clinical research.research.
At the conclusion of three studies, OPTI-misation of MONitoring (OPTIMON)
[50], Strategic Timing of AntiRetrovial Treatment (START) trial Monitoring Substudy
[51] and TargetEd Monitoring: Prospective Evaluation and refinement (TEMPER) study
[52] the scientific community will have a better understanding of effective monitoring
strategies. At the conclusion of all three studies, empirical evidence will be provided and
aid in improving the currently limited published procedures, as all three studies have
different aims and designs in developing audit methodology.
This research is part of a collaborative project and an important opportunity for
clinical trial sites to bring together their existing experience to improve data quality
management systems. It is recommended to further compare what is described in the
literature and what is currently happening at a site level to identify the gaps, the
facilitators and the barriers to implementing data quality management systems. To
achieve the objective of informing the data quality improvement initiative over a broad
spectrum of clinical trials, this critical information needs to be made freely available in
the published literature.

6. Conclusions
This is the first survey gathering information about current data quality tools and
procedures within Australian clinical trial sites. This survey found that clinical trial sites

were implementing newer approaches such as centralized and remote monitoring despite
the majority were still completing 100% SDV, a labor-intensive and cost-inefficient
method. It is clear that data quality management procedures vary greatly between clinical
trials sites, with only 50% of the trial sites with a data management plan in place. Further
research is required to assess differences between data management tools and procedures
between clinical trials within a clinical trial site. This will allow researchers to investigate
what is “standard practice” and focus on developing and implementing publically
available data quality monitoring procedures to ensure data integrity. Data quality is
essential for the reliability of scientific findings generated from the investment in clinical
trials, adequate infrastructure, staff skills, management support and resources need to be
in place to ensure data is effectively managed. It is time that quality assurance and quality
control tools and procedures implemented in clinical trials are cited in all publications.

Clinical Relevance Statement
It is vital to ensure the scientific rigor of clinical trials to evaluate data quality
management procedures and to assure the accuracy of findings and to reduce error. This
survey highlights the heterogeneity of clinical trial’s data quality management practices
in Australia. It thus suggests that ‘best practices’ need to be made freely available in the
published literature. Adequate infrastructure, staff skills, management support and
resources need to be considered and implemented to ensure high quality data and research
are produced and managed effectively.

Multiple Choice Question
Question
1. Which of the following data monitoring methods is the traditional approach that
fulfills the International Conference on Harmonisation Good Clinical Practice
(ICH-GCP) E6 guideline (1996)?
a. Remote monitoring
b. Source data verification
c. Central monitoring
d. Risk-based approach

Answer – B: Source data verification
Explanation: In 1996, the International Conference on Harmonisation (ICH) guideline E6
on Good Clinical Practice (GCP) reported there is a need for on-site monitoring before,
during and after a clinical trial. The practice of source data verification (SDV) fulfils the
ICH-GCP requirements and is a process of comparing data collected on original source
documents to data recorded on a case report form (CRF) or electronic record. Source
documents are considered the “gold standard” from which data is obtained in clinical
trials. Therefore, SDV is considered the traditional approach to monitoring data utilized
by clinical trial auditors.
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Appendix A: Online survey questions
1. Does your institute currently have a clinical data management plan in place?
2. What type of clinical research does your institute conduct?
3. Does your institute have any of the following procedures in place to ensure highquality data is produced?
4. What percentage of your data is monitored?
5. Does your institute have an error acceptance level?
6. Following on from Question 5, if the error rate is found to be higher than the
approved acceptance level, does your institute implement further follow-up
monitoring?
7. How often does your institute conduct internal data monitoring?
8. What variables are included in data monitoring?
9. Does your institute use any of the following sampling techniques to select what
data points are monitored?
10. Please specify the type of staff training/development you conduct that is devoted
to data quality for clinical trials.
11. Who reviews the reports of data quality and consistency?

Table 1: Demographic characteristics of clinical trial site employees
Variable
Gender
Male
Female
Highest level of education
College/TAFE course
Bachelor degree
Doctoral degree
Duration of current employment (years)
0–4
5–9
10 – 15
+ 15
Appointment (current job or position)
Continuing employment (no specified end date)
Fixed-term contract (specified time or ascertainable period) (years)
<1
2
>3
Current job title (n=19)1
Research Fellow
Research Governance Officer
Manager
Clinical Trial/Study Coordinator
Chief Operating Officer
Chief Executive Director

1

One clinical trial employee did not enter the current job title.

n(%)
0(0)
20(100)
1(5)
12(60)
7 (35)
9(45)
7(35)
3(15)
1(5)
9(45)
11(55)
6(45)
2(18)
3(27)
2(10)
1(5)
10(50)
4(20)
1(5)
1(5)

Table 2: Type of clinical trial conducted at each site
Types of Clinical Trial

Treatment
Phase II
Phase III
Quality of life
Prevention
Epidemiology
Phase 1
Phase IV
Screening
Diagnosis
Genetic screening

Number
of Trial
Sites
16
14
14
12
11
11
10
10
9
7
6

Table 3: An outline of survey responses

7(35)
-

Don’t
know
n(%)
3(15)
1(5)

Not
applicable
n(%)
-

11(55)
-

7(35)
5(25)

1(5)

-

3(15)

5(25)

-

4(20)

4(20)

1(5)

5(25)

7(35)

Yes
n(%)
Currently have a clinical data management plan
Procedures to ensure high-quality data
Centralized monitoring
Remote monitoring
Logic, range and consistency checks
On-site source data verification
Statistical techniques
Risk-based targeted monitoring
Risk-based triggered monitoring
Currently have an error acceptance level
Percent of data monitored
10%
20%
75%
100%
Amount of data monitored depends on data point/outcome
measured
Frequency of internal data monitoring
Every month
Every 9 months
Annually
Monitoring completed when data points are identified with
issues of poor quality
Varies between projects and study design
Variables included in data monitoring
Critical data points
Critical and non-critical data points
All (100%) data points
Varies between projects and study design
1
Sampling techniques to select data points
Simple random sampling
Systematic sampling
Stratified sampling
Cluster sampling
Varies between projects and study design

10(50)
19(95)
13(65)
11(55)
11(55)
10(50)
7(35)
5(25)
3(15)
2(10)
14(70)
2(10)
2(10)
2(10)
7(35)

No
n(%)

1(5)
13(65)
2(10)
1(5)
3(15)
1(5)
5(25)
12(60)
1(5)
3(15)
5(25)
3(15)
7(35)
4(20)
2(10)
2(10)
1(5)
1(5)

Centralized monitoring: Data collected through an electronic data capture and queries identified by monitor that may need
further attention to alleviate problems
Remote monitoring: Data monitored off-site, includes delivering documents via email, fax or snail mail to monitors to
conduct source data verification.
Logic, range, and consistency check: Logic check, flag indicator results that fail a common-sense comparison to other
indicator or other disaggregation; Range check, check the value of data to see if it is within a certain range; Consistency
check, performed to determine if the data has an internal conflict and data field correspond
On-site SDV: At the site comparing source data (original or certified copy) document to data recorded or entered to a case
report form or electronic record or database.
Statistic technique: For example cluster and outlier analysis.
Risk-based targeted monitoring: Focus on a certain data point that has been identified to have the most risk.
Risk-based triggered monitoring: After a certain event like a large number of adverse events or deviations further detailed
monitoring occurs.

1

Sampling technique refers to the way data points are selected to be a sample for data monitoring.

Table 4: Type of staff training and development devoted to data quality
Type of training/development
Education throughout clinical trial (as needed)
ICH-GCP training
Group education and training
SOP training
Education prior to research
Skills training and development
One-on-one education and training
Not applicable
Other
ICH-GCP: International Conference on Harmonisation and Good Clinical Practice
SOP: Standard Operating Procedure

n(%)
13(65)
12(60)
11(55)
11(55)
10(50)
7(35)
6(30)
1(5)
1(5)

